We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why Asahi Kasei (AHKSY) Could Be a Top Value Stock Pick
Read MoreHide Full Article
Value investing is always a very popular strategy, and for good reason. After all, who doesn’t want to find stocks that have low PEs, solid outlooks, and decent dividends?
Fortunately for investors looking for this combination, we have identified a strong candidate which may be an impressive value; Asahi Kasei Corporation (AHKSY - Free Report) .
Asahi Kasei in Focus
AHKSY may be an interesting play thanks to its forward PE of 14.3, its P/S ratio of 1, and its decent dividend yield of 1.6%. These factors suggest that Asahi Kasei is a pretty good value pick, as investors have to pay a relatively low level for each dollar of earnings, and that AHKSY has decent revenue metrics to back up its earnings.
But before you think that Asahi Kasei is just a pure value play, it is important to note that it has been seeing solid activity on the earnings estimate front as well. For current year earnings, the consensus has gone up by 7.8% in the past 30 days, thanks to one upward revisions in the past one month compared to none lower.
This estimate strength is actually enough to push AHKSY to a Zacks Rank #1 (the complete list of today’s Zacks #1 Rank (Strong Buy), suggesting it is poised to outperform. You can see the complete list of today’s Zacks #1 Rank stocks here.
So really, Asahi Kasei is looking great from a number of angles thanks to its PE below 20, a P/S ratio below one, and a strong Zacks Rank, meaning that this company could be a great choice for value investors at this time.
Investor Alert: Breakthroughs Pending
A medical advance is now at the flashpoint between theory and realization. Billions of dollars in research have poured into it. Companies are already generating substantial revenue, and even more wondrous products are in the pipeline.
Cures for a variety of deadly diseases are in sight, and so are big potential profits for early investors. Zacks names 5 stocks to buy now.
Image: Bigstock
Why Asahi Kasei (AHKSY) Could Be a Top Value Stock Pick
Value investing is always a very popular strategy, and for good reason. After all, who doesn’t want to find stocks that have low PEs, solid outlooks, and decent dividends?
Fortunately for investors looking for this combination, we have identified a strong candidate which may be an impressive value; Asahi Kasei Corporation (AHKSY - Free Report) .
Asahi Kasei in Focus
AHKSY may be an interesting play thanks to its forward PE of 14.3, its P/S ratio of 1, and its decent dividend yield of 1.6%. These factors suggest that Asahi Kasei is a pretty good value pick, as investors have to pay a relatively low level for each dollar of earnings, and that AHKSY has decent revenue metrics to back up its earnings.
Asahi Kasei Corp. PE Ratio (TTM)
Asahi Kasei Corp. PE Ratio (TTM) | Asahi Kasei Corp. Quote
This estimate strength is actually enough to push AHKSY to a Zacks Rank #1 (the complete list of today’s Zacks #1 Rank (Strong Buy), suggesting it is poised to outperform. You can see the complete list of today’s Zacks #1 Rank stocks here.
So really, Asahi Kasei is looking great from a number of angles thanks to its PE below 20, a P/S ratio below one, and a strong Zacks Rank, meaning that this company could be a great choice for value investors at this time.
Investor Alert: Breakthroughs Pending
A medical advance is now at the flashpoint between theory and realization. Billions of dollars in research have poured into it. Companies are already generating substantial revenue, and even more wondrous products are in the pipeline.
Cures for a variety of deadly diseases are in sight, and so are big potential profits for early investors. Zacks names 5 stocks to buy now.
Click here to see them >>